# Aisling Capital: portfolio, investments and team > Aisling Capital is a private equity based in United States. 55 investments on record, 1 in the last 12 months, latest Oct 2026. Source: https://millionrounds.com/fund/aisling-capital (Millionrounds; every figure on the page links to its filing or article) United States · [Investor](https://millionrounds.com/investors) # Aisling Capital Last cheque observed Oct 2026; 55 cheques on record. Email Deploying now New fund $144M, Jun 2020 Private equity Seed Series A Series B Health Connected-health E-health Follow Aisling Capital and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Faisling-capital) Deploying now **100%** of best year **1** **cheques in 12 months**, 55 on record Since the last cheque **2** days **00** hrs **00** min **00** sec Median round **$313M** Rounds led **0 of 55** Exits **4 from the portfolio** Mostly in **United States, 98%** Pitch Aisling Capital ## Aisling Capital highlights - 01 1 cheques in the last 12 months - 02 Mostly Venture and Series D: 43% of its rounds - 03 4 exits from the portfolio ## What they do > Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies. From their own website - **Type:** Private equity (from a list, unverified) - **Cheque size:** Up to $5.0M as they say - **Stages:** Seed Series A Series B Growth - **Sectors:** Health Connected-health E-health - **Based in:** New York, United States - **Cold pitches:** Not stated ## The record Every round we can evidence, newest first **55 appearances** - **2026** 1 round - **Oct** **[Dren Bio](https://millionrounds.com/company/dren-bio)** US · Wowtale **$350M** With 13 others - **2019** 1 round - **Oct** **[Nuvation Bio](https://millionrounds.com/company/nuvation-bio)** Series A · US · FinSMEs **$275M** With 11 others - **2015** 5 rounds - **Jul** **[ViewRay](https://millionrounds.com/company/viewray)** Venture · US **$27M** With 5 others - **Apr** **[Spirox](https://millionrounds.com/company/spirox)** Series B · US **$19M** With 4 others - **Mar** **[Cynapsus Therapeutics](https://millionrounds.com/company/cynapsus-therapeutics)** Venture · CA **$17M** With 2 others - **Mar** **[Allergen Research Corporation](https://millionrounds.com/company/allergen-research-corporation)** Series B · US **$80M** With 5 others - **Feb** **[Cidara Therapeutics](https://millionrounds.com/company/cidara-therapeutics)** Series B · US **$42M** With 9 others - **2014** 7 rounds - **Oct** **[Syros Pharmaceuticals](https://millionrounds.com/company/syros-pharmaceuticals)** Series B · US **$53M** With 5 others - **Oct** **[Miramar Labs](https://millionrounds.com/company/miramar-labs)** Series D · US **$26M** With 4 others - **Aug** **[Dermira](https://millionrounds.com/company/dermira)** Series C · US **$51M** With 7 others - **Jun** **[Cidara Therapeutics](https://millionrounds.com/company/cidara-therapeutics)** Series A · US **$32M** With 3 others - **Jun** **[PowerVision](https://millionrounds.com/company/powervision)** Series D · US **$10M** With 2 others - **May** **[Loxo Oncology](https://millionrounds.com/company/loxo-oncology)** Series B · US **$24M** With 2 others - **Feb** **[Versartis](https://millionrounds.com/company/versartis)** Series E · US **$55M** With 3 others - **2013** 10 rounds - **Dec** **[ViewRay](https://millionrounds.com/company/viewray)** Venture · US **$30M** With 5 others - **Oct** **[Versartis](https://millionrounds.com/company/versartis)** Series D · US · finsmes.com **$20M** With 5 others - **Oct** **[Loxo Oncology](https://millionrounds.com/company/loxo-oncology)** Series A · US · finsmes.com **$33M** With 1 other - **Oct** **[LensAR](https://millionrounds.com/company/lensar)** Debt · US · biospace.com **$60M** With 2 others - **Jul** **[Versartis](https://millionrounds.com/company/versartis)** Series C · US · sec.gov **$12M** With 3 others - **Jul** **[TRIA Beauty](https://millionrounds.com/company/tria-beauty)** Growth · US · pevc.dowjones.com **$46M** With 6 others - **May** **[ViewRay](https://millionrounds.com/company/viewray)** Series D · US · pehub.com **$15M** With 5 others - **Apr** **[Esperion Therapeutics](https://millionrounds.com/company/esperion-therapeutics)** Venture · US · businesswire.com **$33M** With 5 others - **Mar** **[T2 Biosystems](https://millionrounds.com/company/t2-biosystems)** Series E · US · pevc.dowjones.com **$40M** With 9 others - **Jan** **[Versartis](https://millionrounds.com/company/versartis)** Series C · US · fiercebiotech.com **$25M** With 3 others - **2012** 8 rounds - **Nov** **[Ambit Biosciences](https://millionrounds.com/company/ambit-biosciences)** Venture · US · phx.corporate-ir.net **$50M** With 8 others - **Oct** **[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Series D · US · prnewswire.com **$50M** With 3 others - **Oct** **[TRIA Beauty](https://millionrounds.com/company/tria-beauty)** Venture · US **$7.5M** With 3 others - **Jul** **[Agile Therapeutics](https://millionrounds.com/company/agile-therapeutics)** Series C · US · finsmes.com **$40M** With 5 others - **Mar** **[ViewRay](https://millionrounds.com/company/viewray)** Series C · US · finsmes.com **$45M** With 5 others - **Mar** **[LensAR](https://millionrounds.com/company/lensar)** Venture · US · lensar.com **$24M** With 1 other - **Feb** **[CeNeRx BioPharma](https://millionrounds.com/company/cenerx-biopharma)** Series D · US · onbiovc.com **$4.6M** With 2 others - **Jan** **[Roka Bioscience](https://millionrounds.com/company/roka-bioscience)** Series D · US · prnewswire.com **$48M** With 3 others - **2011** 5 rounds - **Sept** **[ViewRay](https://millionrounds.com/company/viewray)** Venture · US · wraltechwire.com **$10M** With 5 others - **Aug** **[T2 Biosystems](https://millionrounds.com/company/t2-biosystems)** Series D · US · masshightech.com **$23M** With 9 others - **Feb** **[Pharmaron Holding](https://millionrounds.com/company/pharmaron-holding)** Series C · US · earthtimes.org **$40M** With 2 others - **Feb** **[TRIA Beauty](https://millionrounds.com/company/tria-beauty)** Venture · US **$26M** With 3 others - **Jan** **[NextWave Pharmaceuticals](https://millionrounds.com/company/nextwave-pharmaceuticals)** Series C · US · finsmes.com **$45M** With 7 others - **2010** 4 rounds - **Sept** **[TRIA Beauty](https://millionrounds.com/company/tria-beauty)** Venture · US · finsmes.com **$16M** With 3 others - **Aug** **[ViewRay](https://millionrounds.com/company/viewray)** Series C · US · viewray.com **$20M** With 5 others - **Jun** **[Zeltiq Aesthetics](https://millionrounds.com/company/zeltiq-aesthetics)** Series D · US · altassets.com **$25M** With 3 others An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor. ## The team Named by the firm itself, on a filing, its Form ADV or its company registration **4 named** AN **Andrew Newman Schiff** Co-President i Form ADV DJ **Dennis Joseph Purcell** President i Form ADV RJ **Robert John Wenzel** Chief Compliance Officer / Chief Financial Officer i Form ADV SA **Steven Arnote Elms** Co-President i Form ADV We also hold **18** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them. ## What the register says From the firm's own filings with the SEC, which it must file accurately by law **$780M** assets it manages, 2 advisers combined Oct 2026 **Exempt** reporting adviser venture or small private funds - **Legal name:** Aisling Capital LLC - **SEC number:** CRD 157698 Funds on its Form ADV **2** private funds, **$511M** in gross assets · filed Mar 2024 - Aisling Capital IV, L.P. *Private equity* 24 investors $317M - Aisling Capital V, L.P. *Private equity* 39 investors $193M ## What they claim to have backed From their own portfolio page (on their website) **54** of 60 we have independently watched raise [Admabiologics](https://millionrounds.com/company/adma-biologics)[Agiletherapeutics](https://millionrounds.com/company/agile-therapeutics)[Ajaxhealth](https://millionrounds.com/company/ajax-health)[Antiostherapeutics](https://millionrounds.com/company/antios-therapeutics)[Arcusbio](https://millionrounds.com/company/arcus-biosciences)[Armobio](https://millionrounds.com/company/armo-biosciences)[Ascendispharma](https://millionrounds.com/company/ascendis-pharma)[Atreca](https://millionrounds.com/company/atreca)[Avrobio](https://millionrounds.com/company/avrobio)[Biohavenpharma](https://millionrounds.com/company/biohaven-pharmaceutical)[Biomeafusion](https://millionrounds.com/company/biomea-fusion)[Bridgebio](https://millionrounds.com/company/bridgebio)[Calcimedica](https://millionrounds.com/company/calcimedica)[Cempra](https://millionrounds.com/company/cempra)[Cidara](https://millionrounds.com/company/cidara-therapeutics)[Clovisoncology](https://millionrounds.com/company/clovis-oncology)[Colorescience](https://millionrounds.com/company/colorescience)[Compasspathways](https://millionrounds.com/company/compass-pathways)[Dermira](https://millionrounds.com/company/dermira)[Drenbio](https://millionrounds.com/company/dren-bio)[Duratatherapeutics](https://millionrounds.com/company/durata-therapeutics)[Earlens](https://millionrounds.com/company/earlens)[Elevationoncology](https://millionrounds.com/company/elevation-oncology)[F2g](https://millionrounds.com/company/f2g)[Forgebiologics](https://millionrounds.com/company/forge-biologics)[Gene](https://millionrounds.com/company/gene)[Gondolabio](https://millionrounds.com/company/gondolabio)[Harmonybiosciences](https://millionrounds.com/company/harmony-biosciences)[Jnj](https://millionrounds.com/company/jnj)[Lensar](https://millionrounds.com/company/lensar)[Lombardmedical](https://millionrounds.com/company/lombard-medical)[Loxooncology](https://millionrounds.com/company/loxo-oncology)[Meipharma](https://millionrounds.com/company/mei-pharma)[Menlotherapeutics](https://millionrounds.com/company/menlo-therapeutics)[Nuvationbio](https://millionrounds.com/company/nuvation-bio)[Obseva](https://millionrounds.com/company/obseva)[Pellepharm](https://millionrounds.com/company/pellepharm)[Poseida](https://millionrounds.com/company/poseida-therapeutics)[Protagonist-inc](https://millionrounds.com/company/protagonist-therapeutics)[Quintiles](https://millionrounds.com/company/quintiles)[Reneopharma](https://millionrounds.com/company/reneo-pharmaceuticals)[Scholarrock](https://millionrounds.com/company/scholar-rock)[Skinmedica](https://millionrounds.com/company/skinmedica)[Smithersavanza](https://millionrounds.com/company/smithers-avanza)[Sorrentotherapeutics](https://millionrounds.com/company/sorrento-therapeutics)[Sprucebiosciences](https://millionrounds.com/company/spruce-biosciences)[T2biosystems](https://millionrounds.com/company/t2-biosystems)[Treeline](https://millionrounds.com/company/treeline)[Triabeauty](https://millionrounds.com/company/tria-beauty)[Veronapharma](https://millionrounds.com/company/verona-pharma)[Versartis](https://millionrounds.com/company/versartis)[Viewray](https://millionrounds.com/company/viewray)[Viracta](https://millionrounds.com/company/viracta-therapeutics)[Zosanopharma](https://millionrounds.com/company/zosano-pharma) Actavis Advion Aegleabio Aimmune Allergan Ambitbio and 47 more Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded. ## Exits from the portfolio Companies it backed that were later bought or listed **4 in all** **[LensAR](https://millionrounds.com/company/lensar)** Bought by ALPHAEON Corporation **$59M** Nov 2015 **[Ambit Biosciences](https://millionrounds.com/company/ambit-biosciences)** Bought by [Daiichi Sankyo](https://millionrounds.com/fund/daiichi-sankyo) **$410M** Sept 2014 **[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Bought by [Johnson & Johnson](https://millionrounds.com/fund/johnson-and-johnson) **$1.0B** Jun 2013 **[NextWave Pharmaceuticals](https://millionrounds.com/company/nextwave-pharmaceuticals)** Bought by [Pfizer](https://millionrounds.com/fund/pfizer) **Undisclosed** Oct 2012 An exit counts when it came after the firm's first round in the company. From historical deal records. New fund on file **$144M** raised in Jun 2020 From its SEC filing, not a journalist: a firm that has just raised has money to deploy. ## The cheque Seed Series A Series B Median round joined **$313M** the round, not its cheque Led 0 of 55 rounds **0%** - **Said size:** Up to $5.0M - **Sole investor:** Never alone - **Last cheque:** Oct 2026 - **Exits:** 4 from the portfolio Rounds by stage said on their site - Venture *11* - Series D *11* - Series B said *10* - Series C *9* - Series A said *7* - Series E *3* - Seed said *-* Cheques by month Led Joined Nov 2023 Oct 2026 Often in the room with - [OrbiMed](https://millionrounds.com/fund/orbimed) 15 - [Fidelity Biosciences](https://millionrounds.com/fund/fidelity-biosciences) 8 - [Kearny Venture Partners](https://millionrounds.com/fund/kearny-venture-partners) 8 - [F-Prime Capital](https://millionrounds.com/fund/f-prime) 6 - [Vivo Ventures](https://millionrounds.com/fund/vivo-ventures) 6 - [New Leaf Venture Partners](https://millionrounds.com/fund/new-leaf-venture-partners) 5 **Pitching Aisling Capital?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque. Add to your CRM *→* ## Who they invest alongside The investors most often in the same rounds as Aisling Capital. A count of rooms they were both in, not a relationship either has claimed. [**OrbiMed** Private equity **15** rounds together](https://millionrounds.com/fund/orbimed)[**Fidelity Biosciences** Investment firm **8** rounds together](https://millionrounds.com/fund/fidelity-biosciences)[**Kearny Venture Partners** VC firm **8** rounds together](https://millionrounds.com/fund/kearny-venture-partners)[**F-Prime Capital** VC firm **6** rounds together](https://millionrounds.com/fund/f-prime)[**Vivo Ventures** VC firm **6** rounds together](https://millionrounds.com/fund/vivo-ventures)[**New Leaf Venture Partners** VC firm **5** rounds together](https://millionrounds.com/fund/new-leaf-venture-partners)[**De Novo Ventures** Growth equity **4** rounds together](https://millionrounds.com/fund/de-novo-ventures)[**Siemens** Corporate VC **4** rounds together](https://millionrounds.com/fund/siemens)[**Venrock** VC firm **4** rounds together](https://millionrounds.com/fund/venrock)[**Advent Venture Partners** VC firm **3** rounds together](https://millionrounds.com/fund/advent-venture-partners)[**Bay City Capital** VC firm **3** rounds together](https://millionrounds.com/fund/bay-city-capital)[**Blue Chip Venture Company** VC firm **3** rounds together](https://millionrounds.com/fund/blue-chip-venture-company) ## Recently backed The latest companies Aisling Capital put money into. [**Dren Bio** $350M · Oct 2026](https://millionrounds.com/company/dren-bio)[**Nuvation Bio** $275M · Oct 2019](https://millionrounds.com/company/nuvation-bio) ## Quick answers about Aisling Capital ### What does Aisling Capital invest in? Aisling Capital invests most often at Venture and Series D (43% of the rounds on record), in sectors such as Health, Connected-health and E-health. ### How active is Aisling Capital? 55 investments on record, 1 of them in the last 12 months. The most recent was in Oct 2026. ### What has Aisling Capital invested in recently? Its most recent investments on record: Dren Bio (Undisclosed round, Oct 2026) and Nuvation Bio (Series A, Oct 2019). ### How big are Aisling Capital's cheques? The median round it joins is $313M. ### Does Aisling Capital lead rounds? Rarely, if at all: none of its 55 investments on record names it as the lead. ### Where does Aisling Capital invest? Most of the companies it backs are in the United States (98%). ### Is Aisling Capital investing now? Yes: it is actively investing, with 1 investments in the last 12 months. ### Who does Aisling Capital invest alongside? Most often OrbiMed (15 rounds together), Fidelity Biosciences (8 rounds together) and Kearny Venture Partners (8 rounds together). ## Raising now? Find the investors who back rounds like yours, and keep every conversation on one fundraising board. Find similar investorsOpen your CRM Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=aisling-capital) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=aisling-capital)